Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Daniel C. Md Adelman sold 26,784 shares of the business’s stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $40.00, for a total value of $1,071,360.00. Following the completion of the transaction, the insider now directly owns 26,784 shares in the company, valued at approximately $1,071,360. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Aimmune Therapeutics, Inc. (NASDAQ AIMT) opened at $37.83 on Thursday. Aimmune Therapeutics, Inc. has a twelve month low of $15.97 and a twelve month high of $40.65.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.09. sell-side analysts anticipate that Aimmune Therapeutics, Inc. will post -2.51 EPS for the current year.
A number of research firms have recently issued reports on AIMT. Robert W. Baird began coverage on Aimmune Therapeutics in a report on Wednesday, December 20th. They issued an “outperform” rating and a $64.00 target price on the stock. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a report on Saturday, October 21st. Credit Suisse Group boosted their target price on Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. Zacks Investment Research lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, ValuEngine lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $55.43.
WARNING: “Daniel C. Md Adelman Sells 26,784 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://stocknewstimes.com/2018/01/18/daniel-c-md-adelman-sells-26784-shares-of-aimmune-therapeutics-inc-aimt-stock.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.